| Literature DB >> 35156597 |
Jessica R Howard-Anderson1,2, Carly Adams3, Amy C Sherman1, William C Dube1, Teresa C Smith3, Neena Edupuganti4, Minerva Mendez1, Nora Chea5, Shelley S Magill5, Daniel O Espinoza4, Yerun Zhu4, Varun K Phadke1,4, Srilatha Edupuganti1,4, James P Steinberg1, Benjamin A Lopman3, Jesse T Jacob1,2,3, Scott K Fridkin1,2,3, Matthew H Collins1,4.
Abstract
OBJECTIVES: To determine the incidence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel (HCP) and to assess occupational risks for SARS-CoV-2 infection.Entities:
Year: 2022 PMID: 35156597 PMCID: PMC8886081 DOI: 10.1017/ice.2021.518
Source DB: PubMed Journal: Infect Control Hosp Epidemiol ISSN: 0899-823X Impact factor: 3.254
Fig. 1.Results of the enzyme-linked immunoassay (ELISA) assessing SARS-CoV-2 serology status. A participant was considered to have detectable SARS-CoV-2 antibodies if the normalized ratio was ≥0.2 (dotted horizontal line). (A) All 278 participants who did not seroconvert over the 6 months. (B) The 19 participants who had SARS-CoV-2 antibodies at enrollment and were not eligible for the seroconversion outcome. (C) The 26 participants who were seronegative for SARS-CoV-2 at enrollment and had detectable SARS-CoV-2 antibodies at 3 or 6 months.
Characteristics of Healthcare Personnel and Association With SARS-CoV-2 Seroconversion Status Over 6 Months (May–December 2020)
| Variable | Total (n=301), | Seroconversion (n=26), | No Seroconversion | Unadjusted OR (95% CI) | Adjusted OR |
|---|---|---|---|---|---|
| Age <40 y | 172 (57.1) | 15 (57.7) | 157 (57.1) | 1.0 (0.5–2.4) | 0.9 (0.3–2.5) |
| Sex, female | 231 (76.7) | 21 (80.8) | 210 (76.4) | 1.3 (0.5–4) | |
|
| |||||
| Asian | 29 (9.6) | 1 (3.8) | 28 (10.2) | 0.4 (0–2.2) | 0.8 (0–4.9) |
| Black | 33 (11.0) | 7 (26.9) | 26 (9.5) | 3.2 (1.1–8.2) | 4.5 (1.3–14.2) |
| Other/Prefer not to answer | 20 (6.6) | 1 (3.8) | 19 (6.9) | 0.6 (0–3.3) | 0.9 (0–5.2) |
| White | 219 (72.8) | 17 (65.4) | 202 (73.5) | Ref | Ref |
| Hispanic or Latino ethnicity
| 13 (4.3) | 0 (0) | 13 (4.7) | N/A | |
| Immunocompromised
| 24 (8.0) | 5 (19.2) | 19 (6.9) | 3.2 (1.0–8.9) | 3.0 (0.8–9.7) |
|
| |||||
| Administrator | 31 (10.3) | 3 (11.5) | 28 (10.2) | Ref | |
| Nursing | 119 (39.5) | 14 (53.8) | 105 (38.2) | 1.2 (0.4–5.7) | |
| Other healthcare personnel | 72 (23.9) | 6 (23.1) | 66 (24) | 0.8 (0.2–4.2) | |
| Physician/Advance practice provider | 79 (26.2) | 3 (11.5) | 76 (27.6) | 0.4 (0.1–2.1) | |
|
| |||||
| Safety net | 37 (13.5) | 1 (4.2) | 36 (14.3) | 0.2 (0–1.3) | |
| Referral | 129 (46.9) | 13 (54.2) | 116 (46.2) | Ref | |
| Academic community | 63 (22.9) | 5 (20.8) | 58 (23.1) | 0.8 (0.2–2.1) | |
| Community | 46 (16.7) | 5 (20.8) | 41 (16.3) | 1.1 (0.3–3.1) | |
|
| |||||
| Inpatient medical/Surgical floor | 121 (40.3) | 11 (42.3) | 110 (40.1) | 1.4 (0.2–26.6) | |
| Emergency department | 39 (13.0) | 5 (19.2) | 34 (12.4) | 2.1 (0.3–41.3) | |
| Intensive care unit | 69 (23.0) | 4 (15.4) | 65 (23.7) | 0.9 (0.1–17.5) | |
| Outpatient/Other | 15 (5.0) | 1 (3.8) | 14 (5.1) | Ref | |
| No patient care
| 56 (18.7) | 5 (19.2) | 51 (18.6) | 1.4 (0.2–27.4) | |
|
| |||||
| None | 192 (63.8) | 15 (57.7) | 177 (64.4) | Ref | Ref |
| At least some | 109 (36.2) | 11 (42.3) | 98 (35.6) | 1.3 (0.6–3) | 1.1 (0.4–3.2) |
|
| |||||
| ≤50% | 163 (54.2) | 14 (53.8) | 149 (54.2) | Ref | Ref |
| >50% | 138 (45.8) | 12 (46.2) | 126 (45.8) | 1.0 (0.4–2.3) | 1.5 (0.5–5) |
| Performed or present during ≥1 AGP during entire study period
| 172 (57.1) | 16 (61.5) | 156 (56.7) | 1.2 (0.5–2.9) | 1.1 (0.3–4.4) |
|
| |||||
| Yes | 124 (41.2) | 12 (46.2) | 112 (40.7) | Ref | |
| No | 118 (39.2) | 9 (34.6) | 109 (39.6) | 0.8 (0.3–1.9) | |
| No patient care
| 59 (19.6) | 5 (19.2) | 54 (19.6) | 0.9 (0.3–2.5) | |
|
| |||||
| All/nearly all the time | 227 (75.4) | 17 (65.4) | 210 (76.4) | Ref | Ref |
| Less than nearly all the time | 18 (6.0) | 4 (15.4) | 14 (5.1) | 3.5 (0.9–11.2) | 4.0 (0.7–19.5) |
| No patient care
| 56 (18.6) | 5 (19.2) | 51 (18.5) | 1.2 (0.4–3.2) | 1.5 (0.3–8.3) |
| Had a CDC-defined high-risk occupational exposure to SARS-CoV-2
| 37 (12.3) | 3 (11.5) | 34 (12.4) | 0.9 (0.2–2.8) | |
| Close contact with a SARS-CoV-2 infected individual in the community | 30 (10.8) | 4 (17.4) | 26 (10.2) | 1.8 (0.5–5.4) | 2.1 (0.5–6.9) |
| Close contact with a SARS-CoV-2 infected coworker | 42 (15.2) | 2 (8.7) | 40 (15.7) | 0.5 (0.1–1.8) | 0.5 (0.1–1.8) |
| Cumulative incidence of COVID-19 by ZIP code per 1,000, median IQR)
| 30.7 (26.0, 37.0) | 35.5 (29.6, 41.3) | 30.1 (25.8, 36.8) | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) |
|
| |||||
| Used public transportation | 14 (4.7) | 2 (7.7) | 12 (4.4) | 1.8 (0.3–7.2) | |
| Attended a gathering of >10 people during the study period | 176 (58.5) | 13 (50.0) | 163 (59.3) | 0.7 (0.3–1.6) |
Note. All variables are no. (%) unless otherwise stated. AGP, aerosol-generating procedure; CDC, Centers for Disease Control and Prevention; CI, confidence interval; HCP, healthcare personnel; ICU, intensive care unit; IQR, interquartile range; PPE, personal protective equipment; OR, odds ratio.
Survey options for race included American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, other race, or prefer not to answer. Due to small numbers, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander and Other were combined. We excluded participants who preferred not to answer. Ethnicity was examined separately from race in part because of the small number of HCP that self-reported as Hispanic or Latino (all of whom did not seroconvert) and to maintain consistency with our previously published analysis addressing seroprevalence in this sample of HCP at enrollment.
HCP were considered immunocompromised if they had an autoimmune or rheumatologic disorder, active malignancy, solid-organ transplant, hematologic stem cell transplant, or other self-reported immunosuppressive condition or medication.
Participants who stated they did not have patient care roles were not asked this question on the baseline survey.
Excludes HCP where primary location was not able to be determined due to multiple locations being reported.
Includes participants who performed no patient care activities or worked zero shifts in the 2 weeks prior to survey completion.
Participants without patient care were included in the reference group.
The following procedures were specifically included as AGPs: airway suctioning, noninvasive positive pressure ventilation, manual (bag) ventilation, nebulizer treatments, intubation, cardiopulmonary resuscitation, chest physiotherapy, mini-bronchoalveolar lavage, breaking ventilation circuit, sputum induction, bronchoscopy, high-flow oxygen delivery.
A high-risk occupational exposure to SARS-CoV-2 was defined based on the CDC guidance as having prolonged close contact with a patient(s) with SARS-CoV-2 infection while (1) the HCP was not wearing a respirator or face mask; (2) the HCP was not wearing eye protection while the patient was not wearing a face mask or intubated; or (3) the HCP was not wearing all recommended PPE (gown, gloves, eye protection, and respirator) while performing an AGP.
The cumulative incidence of COVID-19 per residential ZIP code was calculated using data from the Georgia Department of Public Health (GDPH) and the US Census Bureau and includes all reported cases of COVID-19 (confirmed and probable) from 1 week prior to enrollment to 1 week prior to 6-month blood draws for each participant.
Fig. 2.Proportion of healthcare personnel reporting the following occupational activities or characteristics at each month: (A) working at least some time in COVID-19 units; (B) working >50% of a typical shift at bedside; (C) performing ≥1 AGP. Note. mo, month; AGP, aerosol generating procedure.
Proportion of Participants Reporting Different Frequencies of PPE Use by Type of AGP Performed in COVID-19 Units
| AGP | Reported Frequency of Use | Average % of Participants Reporting Use
| |||
|---|---|---|---|---|---|
| Gloves | Goggles/ | Gown | N95/PAPR
| ||
| Airway suctioning (n=11)
| Always | 100 | 78.7 | 86.8 | 84.5 |
| Sometimes | 0 | 9.7 | 10.1 | 14.2 | |
| Rarely/never | 0 | 11.6 | 3.1 | 1.3 | |
| CPR (n=8)
| Always | 94.2 | 76.1 | 88.3 | 88.7 |
| Sometimes | 0 | 5.2 | 5.8 | 7.7 | |
| Rarely/never | 5.8 | 18.8 | 5.8 | 3.6 | |
| Intubation (n=9)
| Always | 98.8 | 75.3 | 83.2 | 91.2 |
| Sometimes | 0 | 6.8 | 12.3 | 6.1 | |
| Rarely/never | 1.2 | 17.9 | 4.5 | 2.8 | |
| Noninvasive positive pressure ventilation (n=4)
| Always | 100 | 63.9 | 75.8 | 86.1 |
| Sometimes | 0 | 5.6 | 10.3 | 9.7 | |
| Rarely/never | 0 | 30.6 | 13.9 | 4.2 | |
Note. PPE, personal protective equipment; AGP, aerosol-generating procedure; CPR, cardiopulmonary resuscitation; PAPR, powered air-purifying respirator.
Participants were included if they reported performing AGPs in COVID-19 units only.
Percentages were calculated for each survey (1–6) with the denominators equal to the number of participants who performed/were present for at least 1 of the specific AGP for that survey; percentages were then averaged across surveys.
Participants reported using N95 and PAPR separately; to combine them, we used the greatest amount of time used for either N95 or PAPR.
Average no. of participants for specific AGP per survey, rounded to the nearest whole number.